The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Vertex Pharmaceuticals (NASDAQ:VRTX).
Curious about the top performers within the S&P500 index one hour before the close of the markets on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Stay informed about the performance of the S&P500 index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Wall Street edged lower by midday Tuesday as uncertainty surrounding trade policies lingered, with investors adopting a cautious approach ahead of Wednesday’s Federal Reserve meeting.
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Tuesday to find the gap up and gap down stocks in today's session.
The company’s Q1 revenue missed expectations, but the company raised its 2025 revenue guidance, reflecting optimism about growth drivers like cystic fibrosis treatments and its expanding pipeline.
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company’s full-year revenue guidance of $11.88 billion at the midpoint came in 0.9% below analysts’ estimates. Its non-GAAP profit of $4.06 per share was 5.4% below analysts’ consensus estimates.
Let's have a look at what is happening on the US markets after the closing bell on Monday. Below you can find the top S&P500 gainers and losers in today's after hours session.
